MedTrace Logo

Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases

NCT00814463 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well stereotactic radiosurgery works in treating patients with brain metastases.

Conditions

Interventions

BEHAVIORAL

MMSE

Neurocognitive function via MMSE done every 3 months for length of study.

BEHAVIORAL

QOL via FACT-Br

Quality of Life via FACT-BR every 3 months for length of study.

PROCEDURE

MRI

MRI done every 3 months for the length of the study.

RADIATION

Post-operative SRS

Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • John H. Sampson, MD, PhD · Duke University

  • Hamidreza Aliabadi, MD · Duke University

  • John P. Kirkpatrick, MD · Duke University

  • James E. Herndon, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814463 on ClinicalTrials.gov